Latest News

Newsletter January 2017

CEO comments December has been very busy due to Christmas holidays and because many results had to be brought in from our collaborative partners to start our planning for year 2017. Thanks to Cyxone’s new project manager Leonard Saffer, the process worked very well and we are looking forward to a new, exciting year with […]

Read More

Newsletter December 2016

Message from the CEO The month began with BioEurope in Cologne, where we had meetings with new pharmaceutical companies and companies that can coordinate Cyxone’s regulatory studies (CROs). I met representatives from pharmaceutical companies that are very active in Multiple Sclerosis (MS) and had very good discussions about T20K and Multiple Sclerosis. I also had […]

Read More

Newsletter November 2016

Message from the CEO I am really pleased with the number of people who show an interest in Cyxone, what we are doing, and the progress of T20K. A lot of people communicate with me, and although I try to answer all the queries that come in as best I can I have been busy […]

Read More

Multiple sclerosis: plant peptide could prevent onset of the disease

MedUni Vienna has made a crucial development in the treatment of Multiple Sclerosis (MS): Together with his team and the research group led by Gernot Schabbauer, international partners from Australia, Germany and Sweden, Christian Gruber, Chief Researcher at the Center for Physiology and Pharmacology has demonstrated in an animal model that, following treatment with a […]

Read More

Successful IPO with MedUni Vienna patent

Swedish company Cyxone, a subsidiary of ACCEQUA AB, headquartered in Malmö, recently went public – on the basis of a MedUni Vienna patent application relating to the potential development of an oral medication to combat multiple sclerosis. The invention “Cyclotides as immunosuppressive agents ” is the work of Christian Gruber from the Center for Physiology […]

Read More